Not only for that reason, but also since there is no disease-modifying treatment has been discovered yet for PD, there is still a vital need to develop novel selective MAO-B inhibitors as promising therapeutically active candidates for PD patients. This evidence concerns the gene MAOB and Parkinson disease.